Fibrinogen supplementation is recommended for treatment of severe trauma hemorrhage. However, required dosages and aimed for post-treatment fibrinogen levels remain a matter of discussion. Within the published RETIC study, adult patients suffering trauma-induced coagulopathy were randomly assigned to receive fibrinogen concentrate (FC) as first-line (n = 50) or crossover rescue (n = 20) therapy. Depending on bodyweight, a single dose of 3, 4, 5, or 6 g FC was administered and repeated if necessary (FibA10 < 9 mm). The dose-dependent response (changes in plasma fibrinogen and FibA10) was analyzed. Receiver operating characteristics (ROC) analysis regarding the need for massive transfusion and correlation analyses regarding fibrinogen concentrations and polymerization were performed. Median FC single doses amounted to 62.5 (57 to 66.66) mg.kg⁻¹. One FC single-dose sufficiently corrected fibrinogen and FibA10 (median fibrinogen 213 mg.dL⁻¹, median FibA10 11 mm) only in patients with baseline fibrinogen above 100 mg.dL⁻¹ and FibA10 above 5 mm, repeated dosing was required in patients with lower baseline fibrinogen/FibA10. Fibrinogen increased by 83 or 107 mg.dL⁻¹ and FibA10 by 4 or 4.5 mm after single or double dose of FC, respectively. ROC curve analysis revealed post-treatment fibrinogen levels under 204.5 mg.dL⁻¹ to predict the need for massive transfusion (AUC 0.652; specificity: 0.667; sensitivity: 0.688). Baseline fibrinogen/FibA10 levels should be considered for FC dosing as only sufficiently corrected post-treatment levels limit transfusion requirements.

Background/Objectives: Early fluid resuscitation is a cornerstone of trauma care, but the relationship between resuscitation strategies and acute kidney injury (AKI) remains insufficiently characterized. This study aimed to evaluate whether administration of 4% succinylated gelatin is associated with the development of AKI in critically ill trauma patients during the first seven days of intensive care unit (ICU) treatment. Methods: We conducted an observational retrospective single-center cohort study including 215 adult trauma patients admitted to the ICU at a tertiary care center between 2015 and 2020. Gelatin exposure, kidney function, and clinical outcomes were assessed from the pre-ICU phase through the first ICU week. The primary outcome was the development of AKI, at stage ≥ 2 of the Kidney Disease: Improving Global Outcomes (KDIGO) staging. We used mixed-effects models, competing-risk analyses, correlation analyses and exploratory unsupervised clustering to explore associations between gelatin use and renal outcomes. Results: AKI occurred in 17% of patients and was associated with older age, higher Simplified Acute Physiology Score 3 (SAPS3), pre-existing comorbidities, and early signs of hemodynamic and metabolic compromise. Gelatin doses of ≥10 mL/kg/day were not associated with a consistent rise in serum creatinine or progression of AKI over time. Multivariable regression models revealed no independent association between gelatin and worsening AKI. Instead, KDIGO stage worsening was primarily associated with AKI present at ICU admission and with crystalloid volume. Clustering analysis identified a high-risk phenotype with increased gelatin exposure, but this cluster also showed pronounced shock and inflammation, suggesting confounding by indication. In a competing-risk analysis, gelatin was not associated with new-onset AKI, whereas higher gelatin doses were associated with a lower rate of ICU discharge. Conclusions: In this retrospective cohort of critically ill trauma patients, succinylated gelatin administration showed no statistically significant association with KDIGO-defined AKI progression across unadjusted and adjusted models. Gelatin doses of ≥10 mL/kg/day were more frequently administered in patients with greater hemodynamic instability, suggesting that gelatin use primarily reflected underlying illness severity rather than acting as a direct nephrotoxic agent. These findings provide no evidence of an independent nephrotoxic effect of gelatin when used as part of balanced trauma resuscitation strategies.